MedPath

FERRIPROX

These highlights do not include all the information needed to use FERRIPROX safely and effectively. See full prescribing information for FERRIPROX. FERRIPROX (deferiprone) tablets, for oral useInitial U.S. Approval: 2011

Approved
Approval ID

57bd50e6-c948-0037-4a4b-c8951f70d04a

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Mar 4, 2020

Manufacturers
FDA

ApoPharma USA, Inc.

DUNS: 962810821

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

deferiprone

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code52609-0007
Application NumberNDA021825
Product Classification
M
Marketing Category
C73594
G
Generic Name
deferiprone
Product Specifications
Route of AdministrationORAL
Effective DateApril 27, 2011
FDA Product Classification

INGREDIENTS (8)

Methylcellulose (15 Mpa.S)Inactive
Code: NPU9M2E6L8
Classification: IACT
CrospovidoneInactive
Code: 68401960MK
Classification: IACT
DEFERIPRONEActive
Quantity: 1000 mg in 1 1
Code: 2BTY8KH53L
Classification: ACTIB
Hypromellose 2910 (5 Mpa.S)Inactive
Code: R75537T0T4
Classification: IACT
Magnesium StearateInactive
Code: 70097M6I30
Classification: IACT
Polyethylene Glycol 8000Inactive
Code: Q662QK8M3B
Classification: IACT
HYDROXYPROPYL CELLULOSE (1600000 WAMW)Inactive
Code: RFW2ET671P
Classification: IACT
Titanium DioxideInactive
Code: 15FIX9V2JP
Classification: IACT

Drug Labeling Information

BOXED WARNING SECTION

LOINC: 34066-1Updated: 5/31/2017

WARNING: AGRANULOCYTOSIS AND NEUTROPENIA

RECENT MAJOR CHANGES SECTION

LOINC: 43683-2Updated: 3/4/2020

RECENT MAJOR CHANGES

Dosage and Administration, Recommended Dosage (2.1) 08/2019

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.